Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

NCT04109066 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

521

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

BIOLOGICAL: nivolumab
DRUG: paclitaxel (PTX)
OTHER: nivolumab placebo
DRUG: anthracycline
DRUG: cyclophosphamide
DRUG: Endocrine Therapy
PROCEDURE: Surgery

Sponsor

Bristol-Myers Squibb